Two analyst put a $2.00 to $3.00 PT on AMDA this week, the trading in this stock makes no sense lately, this stock should be much higher like $0.80 to over a dollar higher, and suspect that it's being held down by a hand full of very corrupted naked short hedge funds, who are covering those position but are trying to mask what they are doing with corrupted trading to keep it down before it explodes over $0.60 and burns theim badly,
Amedica Corporation Analyst Rating Update
by Stephanie Nicolas on June 9, 2015
Amedica Corporation (NASDAQ:AMDA): The Company shares has received a rating of Buy from 2 Wall Street Analysts. Amedica Corporation shares have received a Mean Price Target of $2. According to the rating issued from 2 Wall Street Analysts, the High Price Target is seen at $3 while the Lower end of the Price Target is seen at $1. The Median Price Target is calculated at $2.
Amedica Corporation (NASDAQ:AMDA) rose 1.06% or 0.0034 points on Monday and made its way into the gainers of the day. After trading began at $0.33 the stock was seen hitting $0.338 as a peak level and $0.315 as the lowest level. The stock ended up at $0.325. The daily volume was measured at 1,461,125 shares. The 52-week high of the share price is $5.16 and the 52-week low is $0.2035. The company has a market cap of $20 million. According to the SEC Form-4 filing, the Company has disclosed other insider buying and selling activities, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Amedica Corp, Truetzel David W. had sold 15,000 shares worth of $10,200 in a transaction dated December 11, 2014. In this transaction, 15,000 shares were sold at $0.68 per share.
Amedica Corporation (Amedica) is a commercial biomaterial company focused on using its silicon nitride technology platform to develop, manufacture and sell a broad range of medical devices. The Company market spinal fusion products and are developing products for use in total hip and knee joint replacements. The Company markets its Valeo family of silicon nitride interbody spinal fusion devices in the United States and Europe for use in the cervical and thoracolumbar areas of the spine. In addition to its silicon nitride-based spinal fusion products, it markets a complementary line of non-silicon nitride spinal fusion products which allows us to provide surgeons and hospitals with a broader range of products. These products include three lines of spinal fusion devices and five types of orthobiologics, which are used by surgeons to help promote bone growth and fusion in spinal fusion procedures.
AI
